Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

Nat Rev Neurosci. 2002 Oct;3(10):824-8. doi: 10.1038/nrn938.
No abstract available

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / immunology*
  • Alzheimer Disease / prevention & control
  • Alzheimer Disease / therapy*
  • Amyloid beta-Peptides / adverse effects
  • Amyloid beta-Peptides / antagonists & inhibitors
  • Amyloid beta-Peptides / immunology*
  • Amyloid beta-Peptides / therapeutic use
  • Animals
  • Antibodies / immunology
  • Antibodies / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Disease Models, Animal
  • Humans
  • Immunization, Passive / methods*
  • Immunization, Passive / trends
  • Immunotherapy, Active / methods*
  • Immunotherapy, Active / trends
  • Meningoencephalitis / chemically induced
  • Mice
  • Mice, Transgenic
  • Peptide Fragments / immunology
  • Treatment Outcome
  • Vaccines / adverse effects
  • Vaccines / therapeutic use

Substances

  • AN-1792
  • Amyloid beta-Peptides
  • Antibodies
  • Antibodies, Monoclonal
  • Peptide Fragments
  • Vaccines